Stock Financial Ratios

MRNS / Marinus Pharmaceuticals, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price5.67
Volume1,888,800.00
Market Cap ($M)129.05
Enterprise Value ($M)100.17
Book Value ($M)21.48
Book Value / Share1.00
Price / Book3.59
NCAV ($M)20.33
NCAV / Share1.20
Price / NCAV5.59
Income Statement (mra) ($M)
Revenue0.00
EBITDA-28.24
Net Income-28.64
Balance Sheet (mrq) ($M)
Cash & Equivalents37.53
Cash / Share1.92
Assets64.66
Liabilities2.56
Quick Ratio3.75
Current Ratio3.75
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.95
Return on Assets (ROA)-0.91
Return on Equity (ROE)-1.33
Identifiers and Descriptors
CUSIP56854Q101
Central Index Key (CIK)1267813
Industry Groups
SIC 2834 - Pharmaceutical Preparations
Share Statistics
Common Stock Shares Outstanding19,705,120
Common Shares Outstanding21,542,212
Preferred Stock Shares Outstanding0
Scoring Models
Piotroski F-Score1.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Kaplan-Zingales KZ-IndexN/A
Cash Conversion CycleN/A
Per Share Metrics
Assets Current Per Share2.02
Retained Earnings Per Share0.00
Liabilities And Stock Equity Per Share0.00
Assets Other Non Current Per Share0.00
Intangibles Per Share0.00
Cash And Equivalents Per Share1.74
Assets Per Share3.00
Goodwill Per Share0.00
Property Plant And Equipment Net Per Share0.00
Liabilities Current Per Share0.00
Deferred Income Tax Liabilities Per Share0.00
Current Portion Of Long Term Debt Per Share0.00
Property Plant And Equipment Gross Per Share0.00
Accounts Receivable Per Share0.00
Property Plant And Equipment Per Share0.00
Inventory Raw Materials Per Share0.00
Assets Other Current Per Share0.00
Inventory Finished Goods Per Share0.00
Liabilities Other Non Current Per Share0.00
Preferred Stock Value Outstanding Per Share0.00
Assets Non Current Per Share0.00
Accumulated Depreciation And Depletion Per Share0.00
Cash Per Share1.92
Equity Per Share0.00
Minority Interest Per Share0.00
Inventory Work In Progress Per Share0.00
Additional Paid In Capital Per Share0.00
Long Term Debt Per Share0.00
Treasury Stock Per Share0.00
Accounts Payable Per Share0.00
Debt Per Share0.00
Inventory Per Share0.00
Liabilities Per Share0.13

Peers - Pharmaceutical Preparations (2834)

Related News Stories

Finding Biotech Value In All-Time Highs

2018-02-10 seekingalpha
Altum Research is about finding value. While I am definitely not complaining that biotech has rallied, some very interesting companies (SAGE, FATE, PIRS, CBAY, SGMO, etc.) are just too high in price for me to put money in. However there is always value in biotech, sometimes it is just difficult to find! I'm putting up some preliminary names that I'll be following up on in the weeks and months to come. (175-9)

Marinus Pharma's Ganaxolone: If At First You Don't Succeed...

2018-01-22 seekingalpha
The company is currently testing ganaxolone in three areas and has other potential indications on standby. (90-6)

2018 Strategic Outlook: Will Fortune Favor The Bold In Biotech?

2018-01-16 seekingalpha
Significant scientific and technological breakthroughs, combined with unabated M&A appetite and tax reform, provide fertile ground for biotech gains in 2018. (302-8)

Marketplace Authors' Top Picks For 2018

2018-01-06 seekingalpha
We wrap up our Year End Marketplace Roundtable series with the good stuff - authors' sharing some of their best ideas for 2018. (1203-19)

Sage Therapeutics Will Keep Up The Momentum In 2018

2018-01-04 seekingalpha
The shares of Sage Therapeutics have enjoyed more than 200% in 2017 despite the shares pullback in September. (301-3)

CUSIP: 56854Q101